WB Grants $200M for Dengue Prevention

Industry: Healthcare, Healthcare & Pharma
Company: World Bank
Company Intelligence Tag: Business Insights

The World Bank (WB) has approved a $200 million loan to support healthcare services and combat mosquito-borne diseases like dengue in Bangladesh. This funding will enhance primary healthcare services, including treatment, prevention, and medical waste management, in urban areas such as Dhaka North and South City corporations, Chattogram City Corporation, and Savar and Tarabo municipalities. Approximately 2.5 million children under the age of five in these urban areas will benefit from these services.

With Bangladesh’s rapid urbanization and climate change, new health challenges, including dengue outbreaks and various diseases, have emerged. The project aims to improve antenatal services, hypertension screening, and access to healthcare for both women and adults. Additionally, it will focus on environmental health, preventive measures like mosquito control, and behavior change communication to promote healthy lifestyles and address the impact of climate change and air pollution on human health.

The project will also introduce a climate-based dengue early warning system and measures to clear breeding sites to prevent dengue outbreaks. It emphasizes efficient and innovative mosquito control strategies based on climatic conditions.

Source for more details:

Related News

IFC Injects 58M Dollars to Strengthen Renata

May 10, 2025

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Square Pharma Directors Buy Shares Worth Tk 64.58 Crore

April 21, 2025

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

Beximco to Manage Own Firms as HC Cancels Receiver Order

March 15, 2025

The High Court (HC) has canceled its previous order to appoint a receiver for managing Beximco Group companies, allowing them to operate under their own management while being supervised by Bangladesh Bank and other regulatory bodies.

Related News

IFC Injects 58M Dollars to Strengthen Renata

May 10, 2025

The International Finance Corporation (IFC) has committed a $58 million long-term loan to Renata PLC, a prominent pharmaceutical company in Bangladesh, to ease its working capital constraints amid US dollar liquidity challenges. The funding aims to stabilize Renata’s supply chain by enabling secure access to imported Active Pharmaceutical Ingredients (APIs), vital for uninterrupted medicine production.

ACI Logs Tk 13.69 Crore Loss In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, ACI Limited reported a consolidated loss of Tk 13.69 crore, a sharp decline from a Tk 1.65 crore profit in the same period last year, despite a 17% year-on-year revenue growth to Tk 3,573.50 crore.

Renata Profit Falls To Tk 58 Crore In Q3 FY 2024–25

May 6, 2025

In Q3 of FY 2024–25, Renata PLC’s profit fell 20% year-on-year to Tk 58 crore, despite a 16% rise in sales to Tk 1,070 crore, driven by strong domestic demand. However, profits declined due to a 100% surge in finance costs, reaching Tk 45 crore from Tk 23 crore, amid rising interest rates.

Square Pharma Profit Hits Tk 605 Crore In Q3 FY2024-25

May 4, 2025

In Q3 of FY2024-25, Square Pharmaceuticals reported an 18% year-on-year profit increase, reaching Tk 605 crore, while revenue rose 22% to Tk 2,012 crore. Its EPS climbed to Tk 6.83 from Tk 5.55, and for the July–March period, EPS reached Tk 21.15, up from Tk 18.24.

Square Pharma Directors Buy Shares Worth Tk 64.58 Crore

April 21, 2025

Two directors of Square Pharmaceuticals, Samuel S Chowdhury and Ratna Patra, each purchased 15 lakh shares, totaling Tk 64.58 crore, based on the DSE’s disclosed closing price of Tk 215.40 per share. These transactions, declared earlier in March, reflect continued confidence in the company, whose shares rose 0.05% during morning trading.

Beximco to Manage Own Firms as HC Cancels Receiver Order

March 15, 2025

The High Court (HC) has canceled its previous order to appoint a receiver for managing Beximco Group companies, allowing them to operate under their own management while being supervised by Bangladesh Bank and other regulatory bodies.

BUSINESSMONITOR

Connect with


Dont Have Account? Please register Here